Kamada Expands Plasma Operations with San Antonio Facility FDA Clearance
Kamada Ltd. has achieved a significant milestone in its North American expansion strategy, securing FDA approval for its newly constructed plasma collection center in San Antonio, Texas, following a regulatory inspection conducted in February 2026. The approval positions the Israeli-headquartered biopharmaceutical company to substantially scale its specialty plasma collection operations, a critical component of its sourcing strategy for manufacturing plasma-derived therapies. This development represents a meaningful step forward in Kamada's broader growth initiative to establish itself as a major player in the competitive U.S. plasma collection market.
Strategic Infrastructure Investment Bears Regulatory Fruit
The San Antonio facility spans 11,100 square feet and has been engineered with substantial collection capacity in mind. At full operational capacity, the center is projected to collect approximately 50,000 liters of plasma annually—a considerable volume that underscores the significance of this investment. More importantly for investors, the facility is anticipated to generate $8 to $10 million in annual revenues from normal source plasma sales once it reaches optimal capacity levels.
Key characteristics of the San Antonio operation include:
- Geographic significance: Positioned as one of the largest specialty plasma collection centers in the United States
- Capacity metrics: 50,000 liters per year projected at full operations
- Revenue potential: $8-10 million annually in steady-state revenues
- Infrastructure: 11,100 square foot purpose-built facility
- Strategic positioning: Third major collection hub complementing existing Texas operations
The approval follows the company's established presence in the region, as Kamada maintains existing plasma collection operations in Houston and Beaumont, Texas. This Texas-centric concentration reflects the state's significant advantages as a plasma collection hub, including favorable demographics, established supply chains, and established regulatory relationships with state authorities.
Market Context: Plasma Collection in a Consolidating Landscape
The plasma collection industry remains a vital segment of the broader biopharmaceutical ecosystem, as plasma-derived therapies treat numerous rare and chronic conditions. The U.S. plasma market has experienced steady consolidation, with several large players controlling significant market share. Kamada's expansion strategy directly addresses the persistent demand for high-quality, specialty plasma sources required by manufacturers of immunoglobulins, clotting factors, and albumin-based therapies.
The timing of this approval reflects the broader industry trend toward vertical integration, whereby plasma-derived manufacturers increasingly control their upstream sourcing through proprietary collection facilities rather than relying solely on third-party suppliers. For Kamada, which manufactures specialty plasma-derived products including immunoglobulins and other biologics, owning collection infrastructure provides several strategic advantages: improved supply chain reliability, better cost control, and reduced exposure to external supplier fluctuations.
Competitors in the plasma collection space, including larger diversified biopharmaceutical companies, continue investing in collection infrastructure. The regulatory approval landscape has become more rigorous in recent years, making Kamada's successful navigation of FDA inspection and approval particularly noteworthy. The February 2026 inspection and subsequent approval demonstrate the company's operational readiness and compliance standards, important credentials for an operation seeking to become "one of the largest specialty plasma collection centers in the U.S."
Investor Implications: Revenue Visibility and Strategic Optionality
For Kamada shareholders, this approval carries several material implications. First, it provides revenue visibility—the $8-10 million annual revenue potential represents a meaningful addition to the company's top line once full capacity is achieved. Given the relatively low operating margins typically associated with plasma collection startups, ramp-up timing will be critical for investors tracking profitability trajectories.
Second, the San Antonio facility enhances Kamada's strategic optionality. Control of upstream plasma sourcing strengthens the company's negotiating position with customers, reduces supply chain vulnerability, and potentially improves the economics of its downstream manufacturing operations. From a competitive positioning standpoint, the company now has three geographically distributed collection centers in Texas, creating a regional hub that could serve as a model for expansion into other high-potential states.
Third, the approval validates Kamada's operational and regulatory execution capabilities. Successfully navigating FDA inspection and approval for a new collection facility demonstrates management competence in a highly regulated environment—an important signal for investors evaluating the company's ability to execute future growth initiatives.
Investors should monitor several metrics as the facility ramps: actual collection volumes relative to the 50,000-liter projection, revenue realization timing, and operating margins on plasma sales. Additionally, any announcements regarding expanded capacity, additional facility construction, or strategic partnerships in plasma sourcing would indicate accelerating growth plans.
Looking Ahead: Foundation for Continued Expansion
The San Antonio facility approval establishes important infrastructure for Kamada's continued presence in the North American plasma market. Whether this represents the beginning of a broader geographic expansion strategy or remains focused on the Texas market will be important for investors to clarify during future earnings calls and guidance updates. The company's ability to rapidly ramp the San Antonio facility to full capacity while maintaining high collection quality and regulatory compliance will be closely watched by industry observers and investors alike. For Kamada, this FDA approval represents validation of its strategic vision to build integrated plasma-derived biopharmaceutical operations with secure, proprietary sourcing—a competitive advantage increasingly valued in the specialty pharma landscape.